Surgical Resection for Hepatocellular Carcinoma

NCT06013657 | Completed

• 1 other identifier: DRCiptoMGH 19-11-1313
• Study Type: observational
• Target: 91
• Locations: 1 country
• Sites: 1

Brief Summary

Hepatocellular carcinoma is a type of liver cancer and is one of the leading causes of global cancer death. Surgical resection of the afflicted areas of the liver is one of the treatment methods for this condition. In this retrospective research, the investigators explore the outcomes of liver resection for hepatocellular carcinoma patients undergoing liver resection from 2010 to 2021 in Cipto Mangunkusumo General Hospital, Jakarta. The main outcome is mortality and the secondary outcomes are factors predicting mortality after resection.

Conditions

Resectable Hepatocellular Carcinoma

Keywords

carcinoma,hepatocellular; liver neoplasms; hepatectomy; mortality; prognostic

Outcome Measures

Primary Outcomes (1)

• Mortality

  Mortality status of patients

  Through study completion, an average of 3 years

Secondary Outcomes (14)

• Age

  Within one week before surgery

• Sex

  Within one week before surgery

• Etiology

  Within one month before surgery

• Child-Pugh classification

  Within one month before surgery

• BCLC Classification

  Within one month before surgery

Study Arms (1)

Liver resection

Patients undergoing liver resection due to hepatocellular carcinoma from 2010 to 2021 in RSCM, Jakarta, an academic tertiary-level national referral hospital in Indonesia.

Procedure: Liver Resection

Interventions

Liver Resection PROCEDURE

Resection of a part of the liver afflicted by hepatocellular carcinoma

Also known as: Hepatectomy

Liver resection

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study used a total population sampling of all patients undergoing liver resection in Cipto Mangunkusumo hospital due to a confirmed diagnosis of hepatocellular carcinoma from 2010 to 2021. Patients undergoing liver resection in other hospitals were excluded, even though diagnosis or further care is done in RSCM. In addition, patients with other malignancies or undergoing other treatment methods were excluded.

You may qualify if:

• Patients undergoing liver resection in Cipto Mangunkusumo hospital due to a confirmed diagnosis of hepatocellular carcinoma from 2010 to 2021

You may not qualify if:

• Patients undergoing liver resection in other hospitals were excluded, even though diagnosis or further care is done in Cipto Mangunkusumo hospital
• Patients with other malignancies
• Patients undergoing other treatment methods for hepatocellular carcinoma.

Sponsors & Collaborators

• Dr Cipto Mangunkusumo General Hospital: lead

Study Sites (1)

Dr. Cipto Mangunkusumo General Hospital

Jakarta Pusat, DKI Jakarta, 10440, Indonesia

Location

MeSH Terms

Conditions

Carcinoma, Hepatocellular; Liver Neoplasms

Interventions

Hepatectomy

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases

Intervention Hierarchy (Ancestors)

Digestive System Surgical Procedures; Surgical Procedures, Operative

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal investigator

Study Record Dates

• First Submitted: August 15, 2023
• First Posted: August 28, 2023
• Study Start: December 1, 2021
• Primary Completion: March 25, 2022
• Study Completion: June 1, 2022
• Last Updated: August 28, 2023

Record last verified: 2023-08

Locations

ID (1)